Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$492.97M+1163.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helen I. Torley
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 423
- Beta
- 0.90
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.38
Financials
Revenue
$492.97M+1163.9%Net Income
$247.05MEBITDA
$330.88MFree Cash Flow
$255.22MEPS (diluted)
$2.01Shares Outstanding (diluted)
122.61M-4.3%Operating Expenses
$86.02MCash & Debt
$1.07BReturn of Capital
$67.27MRevenue by Segment (annual)
$1.62BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.40B | $316.89M | $2.64 |
| 2024 | $1.02B | $444.09M | $3.50 |
| 2023 | $829.25M | $281.59M | $2.13 |
| 2022 | $660.12M | $202.13M | $1.48 |
| 2021 | $443.31M | $402.71M | $2.86 |
| 2020 | $267.59M | $129.09M | $0.95 |
| 2019 | $195.99M | $-72.24M | $-0.50 |
| 2018 | $151.86M | $-80.33M | $-0.56 |
| 2017 | $316.61M | $62.97M | $0.46 |
| 2016 | $146.69M | $-103.02M | $-0.81 |
| 2015 | $135.06M | $-32.23M | $-0.25 |
| 2014 | $75.33M | $-68.38M | $-0.56 |
| 2013 | $54.80M | $-83.48M | $-0.74 |
| 2012 | $42.33M | $-53.55M | $-0.48 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.89
- Implied price
- $97.13
- Return from $91.35
- 1.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.29 — -47.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -2.0% | -15.0% | -11.3% | -8.1% | -5.4% | -2.9% |
| 3.0% | -10.6% | -6.8% | -3.5% | -0.5% | 2.1% |
| 8.0% | -6.3% | -2.2% | 1.2% | 4.3% | 7.0% |
| 13.0% | -1.9% | 2.3% | 5.9% | 9.1% | 12.0% |
| 18.0% | 2.4% | 6.8% | 10.6% | 13.9% | 16.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (57)
- 4chan /biz/biz·10h ago·Neutral
>>62950697 Google HALO trade/stocks. AIs are opposite of that. High upkeep.
View source ↗ - News (Marketaux)seekingalpha.com·1d ago·Neutral
Halozyme Therapeutics: Paying Today For A Next Wave Nobody Can See Yet Based on Halozyme Therapeut[+24 characters]
View source ↗ - News (RSS)seekingalpha·1d ago·Neutral
Halozyme Therapeutics: Paying Today For A Next Wave Nobody Can See Yet
View source ↗ - Newszacks.com·2d ago·Positive
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down Halozyme faces a legal setback in Germany as a court overturns an injunction against Merck's Keytruda SC, prompting a new patent lawsuit.
View source ↗ - Newsseekingalpha.com·3d ago·Negative
Halozyme Therapeutics: 3 Technologies, Multiple Big Pharma Partnerships Halozyme Therapeutics, Inc. shares are under pressure due to concerns about slowing sequential revenue growth and the broader selloff in AI-related stocks. However, HALO has three drug delivery technologies and partnerships with major pharmaceutical companies. Notably, HALO royalty revenue grew 44.5% year-over-year to $341 million in Q3.
View source ↗ - Newsprnewswire.com·3d ago·Neutral
Halozyme Provides Update on German Preliminary Injunction Hearing SAN DIEGO, Nov. 19, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering Keytruda SC in Germany. "We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in German…
View source ↗ - Newszacks.com·5d ago·Positive
HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock? Halozyme surges 43.1% in six months on strong ENHANZE-driven royalties and higher revenue guidance.
View source ↗ - Newszacks.com·12d ago·Negative
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newszacks.com·12d ago·Negative
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
View source ↗ - Newszacks.com·16d ago·Positive
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
View source ↗ - Newszacks.com·16d ago·Neutral
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
View source ↗ - Newsprnewswire.com·16d ago·Negative
…al extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous …
View source ↗ - News (Marketaux)seekingalpha.com·16d ago·Neutral
Halozyme Therapeutics, Inc. (HALO) Q3 2026 Earnings Call Transcript Halozyme Therapeutics, Inc. (HALO) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches.
View source ↗ - Newszacks.com·17d ago·Negative
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·18d ago·Neutral
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newszacks.com·23d ago·Neutral
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
View source ↗ - Newszacks.com·24d ago·Neutral
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsprnewswire.com·31d ago·Neutral
Halozyme to Report Third Quarter 2026 Financial and Operating Results SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading. Halozyme will host a conference call on Thursday, November 5, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
View source ↗ - Newsfxempire.com·32d ago·Positive
Halozyme's Strong Earnings Growth Sends Shares Higher Halozyme Therapeutics, Inc. (HALO) shares are up 910% since March 2014.
View source ↗ - 4chan /biz/biz·38d ago·Neutral
HALO W >>>/pol/544352103
View source ↗ - Newszacks.com·39d ago·Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newszacks.com·39d ago·Neutral
Why Investors Need to Take Advantage of These 2 Medical Stocks Now The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
View source ↗ - News (Marketaux)gurufocus.com·40d ago·Positive
HALO Maintained by TD Cowen -- Price Target Raised to $130 Halozyme Therapeutics [+236 characters]
View source ↗ - Newszacks.com·40d ago·Neutral
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·45d ago·Neutral
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
View source ↗ - News (RSS)seekingalpha·46d ago·Positive
Halozyme wins Dutch patent ruling against Merck’s Keytruda SC
View source ↗ - Newszacks.com·46d ago·Neutral
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
View source ↗ - Newsprnewswire.com·46d ago·Negative
…nction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, h…
View source ↗ - Newsprnewswire.com·53d ago·Neutral
Halozyme Announces Appointment of Jim Daly to its Board of Directors SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
View source ↗ - Newsdefenseworld.net·59d ago·Neutral
Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX) Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Ratings This is a breakdown of recent ratings
View source ↗ - Newszacks.com·60d ago·Neutral
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - News (RSS)seekingalpha·65d ago·Neutral
Halozyme prices $1.3B convertible senior notes offering due 2033
View source ↗ - News (RSS)investing·65d ago·Neutral
Halozyme prices $1.3 billion convertible notes offering
View source ↗ - Newsprnewswire.com·65d ago·Neutral
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
View source ↗ - Newsprnewswire.com·67d ago·Neutral
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
View source ↗ - Newszacks.com·67d ago·Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
View source ↗ - News (RSS)seekingalpha·68d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsfxempire.com·72d ago·Neutral
Record Revenue Growth Boosts Halozyme Shares Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Halozyme to Participate at Upcoming Investor Conferences SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.
View source ↗ - Newsseekingalpha.com·82d ago·Negative
…icing The Second Growth Wave Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.
View source ↗ - Newszacks.com·83d ago·Positive
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·86d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsfeeds.newsfilecorp.com·88d ago·Neutral
Cleantek Industries Secures Sale of HALO SE Units for Deployment in Alaska Calgary, Alberta--(Newsfile Corp. - August 26, 2026) - Cleantek Industries Inc. (TSXV: CTEK) ("Cleantek" or the "Company"), a leading provider
View source ↗ - Newsseekingalpha.com·90d ago·Positive
Halozyme Therapeutics: Running Through 2027 Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO's performance in the current year. HALO's stock performance has delivered significant returns, validating the earlier investment case and strategic positioning.
View source ↗ - Newszacks.com·93d ago·Positive
HALO Stock Rises 36% in a Month: Here's What You Should Know Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
View source ↗ - Newsprnewswire.com·96d ago·Neutral
Halozyme Appoints Dannielle Appelhans to its Board of Directors SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
Sagtec Officially Launches HALO AI and Secures US$3 Million Purchase Order for 1,500 AI Food-Serving Robots from Dubai Distributor Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment
View source ↗ - 4chan /biz/biz·100d ago·Neutral
>>62594520 I'll probably just go with SCHD it's similar to HALO but with better companies
View source ↗ - 4chan /biz/biz·100d ago·Neutral
>>62594498 Did you hear about the new HALO ETFs? LOHA and HALX HALO = heavy assets low obsolence The idea is these are capital intensive companies, with large real world presences that are difficult to disrupt.
View source ↗ - 4chan /biz/biz·100d ago·Neutral
…raps. So continuing with requirements >must weed out disrupted value traps via whatever means I have some suggestions of how that could be done. Maye it could be a HALO fund, with heavy, capital intensive assets, and big moats. Or whatever. I don't really care how they weed out disrupted value traps, I just want it to. Without actually just buying growth. It has to be value. Another idea, maybe it could be free cash flow. Maybe it could be a combination of things. I don't care. As long as it w…
View source ↗ - News (RSS)marketwatch·101d ago·Neutral
These nontech stocks can ride the AI build-out for years Massive spending on data centers and AI infrastructure can benefit “HALO” companies: hard assets, low obsolescence.
View source ↗ - Newszacks.com·101d ago·Neutral
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - 4chan /biz/biz·102d ago·Positive
Do you know about the HALO trade? Heavy Assets Low Obsolescence HALO It's become basically the counter AI trade. HALO companies are companies with high capital costs, and heavy assets. And big moats. Like a manufacturing company, like Ford or some s***, or Walmart. It's had a low correlation with the AI trade. There's some new HALO etfs, but they have like 70 bps fees or some s***. I'll show you a HALO ETF with dirt cheap fees. SCHD. It's not a perfect HALO tracker but it's like 90% there. A
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $2.60 per share
Typical surprise +5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$2.39 vs $2.30beat
- Thu, Aug 6$2.28 vs $1.79beat
- Mon, May 11$1.60 vs $1.55beat
- Tue, Feb 17$-0.24 vs $2.15miss
- Mon, Nov 3$1.72 vs $1.63beat
- Tue, Aug 5$1.54 vs $1.23beat
Estimates and results for HALO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HALO officers and directors.
- Bought
- —
- Sold
- $29.5m
0 trades
57 trades
- Posard Matthew L.sold
- Posard Matthew L.sold
- Torley Helensold
- Torley Helensold
- Torley Helensold
- Torley Helensold
- Torley Helensold
- Torley Helensold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (30d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 7, 2025 (14d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (24d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 13, 2023 (38d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 5, 2020 (14d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (17d later)Buy$1,001 - $15,000
- Mark Warnersenate · VA · disclosed Dec 8, 2017 (32d later)Sell$500,001 - $1,000,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
